Investor call, page-7

Nothing new discussed however they were still extremely confident of a positive CE Mark determination. While the Brexit machinations have no bearing on the Oncolsil certificate when issued, there was a sense that the overall workload imosed on BSI by Brexit has slowed down the Oncosil review. Also some good clarification on the resection rates/R0 rates compared to literature review which suggests that resection rate with same chemo drugs alone c15% vs. 24% combined with Oncosil. Directors expected 4-5 resections (10%) heading into the study. This bodes well for redesigning the pivotal study in the US to potential cover different endpoint(s) and reduce sample size